Recently, EGFR, mTOR, and Poly (ADP-ribose) polymerase (PARP) inhibitors were among the therapeutic agents being studied in patients with TNBC and BRCA1-associated breast cancers[4]. Here, BRCA1 is linked to breast carcinoma.